Tuesday, October 20-Thursday, October 22
World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
July 23, 2026
Posts
Patients with newly diagnosed #MultipleMyeloma may be eligible to participate in #ClinicalTrial EAA181/EQUATE. Learn more here: https://bit.ly/eaa181equate cc: @myelomaMD, @mtmdphd
5. Lenalidomide for 2 years is as good as giving it indefinitely. (ENDURANCE trial) @NEJM 2026
This is an investigator initiated @theNCI funded clinical trial that I think is practice changing; reduces toxicity; and saves the country billions of $
Took 15 years start to finish.
Dear Dr. Rajkumar- This is very inspirational, and thx for all your /team’s contributions to the field. You are a role model for many of us. For all faculty interested in MM attending the co-operative group calls @eaonc @SWOG @ALLIANCE_org listening to leaders and interacting
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
32
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
